Anaplastic lymphoma kinase (ALK)-inhibitor sequencing for patients with ALK-positive non-small cell lung cancer
CDA-AMC
Record ID 32018016010
English
Authors' objectives:
Canada’s Drug Agency received a request to identify evidence and evidence-based guidelines available on the sequencing of ALK-targeted therapies in ALK-positive non–small cell lung cancer in the second-line and subsequent-line settings. Outcomes of interest include clinical benefits (e.g., overall survival, progression-free survival, death attributable to lung cancer, objective response, intracranial response or intracranial progression-free survival, and health-related quality of life) and safety outcomes (e.g., treatment-emergent adverse events, serious adverse events, and adverse events of special interest). This review will employ a hierarchical approach to evidence inclusion, prioritizing the most robust and current evidence. If no suitable systematic reviews are identified, or if supplemental information is needed, randomized controlled trials will be included.
Details
Project Status:
Ongoing
URL for project:
https://www.cda-amc.ca/anaplastic-lymphoma-kinase-alk-inhibitor-sequencing-patients-alk-positive-non-small-cell-lung
Anticipated Publish Date:
2027
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Canada
MeSH Terms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Anaplastic Lymphoma Kinase
- Protein Kinase Inhibitors
- Pharmacogenomic Testing
Contact
Organisation Name:
Canada’s Drug Agency (CDA-AMC)
Contact Address:
865 Carling Ave., Suite 600 Ottawa, ON Canada K1S 5S8
Contact Name:
Shannon Nordstrom
Contact Email:
shannon.nordstrom@cda-amc.ca
Copyright:
2025 Canadian Agency for Drugs and Technologies in Health
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.